Solid State Pharmaceutics

Solid State Pharmaceutics

Research focus

The research in the Solid State Pharmaceutics group is naturally centred on the solid state of pharmaceutical preparations. In the area of small molecular drug molecules, an increasing portion of drugs shows low aqueous solubility. This low solubility often severely reduces the bioavailability of the drug and may lead to pharmacologically effective molecules being abandoned. The transformation of a drug from the crystalline state to a high-energy amorphous form generally leads to an increase in solubility. However, as the amorphous form is inherently unstable, technological approaches are necessary to stabilise amorphous drugs. In our group, these include stabilizing excipients such as polymeric carriers, small molecules in co-amorphous formulations as well as mesoporous silica. Furthermore, we have developed approaches that allow an in situ amorphization of the crystalline drug in the final dosage form, e.g. by microwaves, which potentially allows to circumvent the long-term stabilization of the amorphous drug.

“The most active form of a drug frequently is an unstable variant and our research thus focusses on stabilizing the unstable” says group leader Dr. Holger Grohganz. With regard to larger molecules such as proteins, freeze-drying is widely used in production, although the interactions between various excipients and proteins are not fully understood. Our aim is to obtain a deeper understanding of the influence of various composition and process parameters on the solid state form of both the excipient and the macromolecule.

 

 

Staff at Solid State Pharmaceutics Group

Group leader: Holger Grohganz